Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28148666 | 0.98 | OPRM1 (0.59) | OPRM1OPRL1OPRK1SLC6A4GRIN2D | |
| SCHEMBL294583 | 0.98 | OPRM1 (0.63) | OPRM1OPRL1OPRK1SLC6A4GRIN2D | |
| SCHEMBL294971 | 0.93 | OPRM1 (0.63) | OPRM1OPRL1OPRK1SLC6A4GRIN2D | |
| SCHEMBL1822928 | 0.89 | OPRM1 (0.74) | OPRM1OPRL1OPRK1SLC6A4 | |
| Hydrochloric Acid SCHEMBL28226628 | 0.86 | OPRM1 (0.71) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL7552235 | 0.79 | OPRM1 (0.58) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL5327730 | 0.79 | GRIN2D (0.46) | SLC6A4GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL5671696 | 0.79 | OPRM1 (0.58) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL3663027 | 0.79 | SLC6A3 (0.56) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL5036687 | 0.79 | OPRM1 (0.58) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649044-B1 | METHOD FOR SYNTHESISING SUBSTITUTED AMINOCYCLOHEXANONE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2017-09-20 | — | — | EP | disclosed |
| CN-101394847-B | Cycloalkylamines as monoamine reuptake inhibitors | 塞普拉柯公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-105473575-A | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2016-04-06 | — | — | CN | disclosed |
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| EP-2240474-B1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| CN-101910162-A | Cyclic pyridyl-N- [1,3,4] -thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2010-12-08 | — | — | CN | disclosed |
| EP-1937659-B1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-2240474-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| CN-101282952-A | Cyclic N- [1,3,4] -thiadiazol-2-yl-benzene sulfonamides, process for their preparation and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-10-08 | — | — | CN | disclosed |
| EP-1937659-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007020502-A2 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1296934-A1 | CYCLOHEXYLAMINE DERIVATIVES AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001092204-A1 | CYCLOHEXYLAMINE DERIVATIVES AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6060484-A | Anti-viral method | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1997041846-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806205-A2 | Urea, thiourea and guanidine compounds and their use as anti-viral agents | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| CN-87104030-A | OPTICALLY ACTIVE ADSORBENTS | — | 1987-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | OPRM1 3188/4885OPRL1 2675/4885OPRK1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.